REVIEW

Use of Benzodiazepines in Alzheimer’s Disease: A Systematic Review of Literature

Michaela Defrancesco, MD, PhD, MSc; Josef Marksteiner, MD; W. Wolfgang Fleischhacker, MD; Imrich Blasko, MD, MSc

Memory Clinic (Dr Defrancesco), and Division of General and Social Psychiatry (Drs Fleischhacker and Blasko), Department of Psychiatry and Psychotherapy, Innsbruck Medical University, Innsbruck, Austria; Department of Psychiatry and Psychotherapy A, Landeskrankenhaus Hall, Hall, Austria (Dr Marksteiner); Division of Biological Psychiatry, Department of Psychiatry and Psychotherapy, Innsbruck Medical University, Innsbruck, Austria (Dr Fleischhacker).

Correspondence: Michaela Defrancesco, MD, PhD, MSc, Department of Psychiatry and Psychotherapy, Division of General and Social Psychiatry, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria (Michaela.Defrancesco@i-med.ac.at).

Abstract

Background: Benzodiazepines are frequently prescribed in patients with Alzheimer’s disease. Unfortunately, studies evaluating their benefits and risks in these patients are limited.

Methods: Clinical trials focusing on the effect of benzodiazepines on cognitive functions, disease progression, behavioral symptoms, sleep disturbances, and the general frequency of benzodiazepine use were included in this review. Published articles from January 1983 to January 2015 were identified using specific search terms in MEDLINE and PubMed Library according to the recommendations of The Strengthening the Reporting of Observational Studies in Epidemiology initiative.

Results: Of the 657 articles found, 18 articles met predefined selection criteria and were included in this review (8 on frequency, 5 on cognitive functions, 5 on behavioral and sleep disturbances). The frequency of benzodiazepine use ranged from 8.5% to 20%. Five studies reported accelerated cognitive deterioration in association with benzodiazepine use. Two studies reported clinical efficacy for lorazepam and alprazolam to reduce agitation in Alzheimer’s disease patients. No evidence was found for an improvement of sleep quality using benzodiazepines.

Conclusion: This systematic review shows a relatively high prevalence of benzodiazepine use but limited evidence for clinical efficacy in Alzheimer’s disease patients. However, there is a paucity of methodologically high quality controlled clinical trials. Our results underscore a need for randomized controlled trials in this area.

Keywords: Benzodiazepines, Alzheimer’s disease, behavioral and psychological symptoms of dementia, sleep disorder, agitation

Introduction

Recently, a number of studies have examined the possible links between Benzodiazepines (BZD) use and Alzheimer’s disease (AD). Findings from retrospective studies suggest that cumulative exposure to BZD longer than 3 month may increase dementia risk (Lagnaoui et al., 2002; Billioti de Gage et al., 2014). Particularly, the use of BZD with a long half-life may be most harmful by limiting the cognitive reserve capacity (Billioti de Gage et al., 2012). AD is the most common cause of dementia among the elderly. It is estimated that the number of patients with AD will triple by 2050 to more than 115 million cases worldwide (Alzheimer's,
Although cognitive deficits are the clinical hallmark of AD, various noncognitive symptoms termed behavioral and psychological symptoms of dementia (BPSD) are common and can dominate disease presentation (Lyketsos et al., 2000, 2002). BPSD have been observed in up to 60% to 98% of patients with dementia and include agitation, aggression, anxiety, delusions, sleep disturbances, and hallucinations among other symptoms (Mega et al., 1996; Margallo-Lana et al., 2001). To date, there is still disagreement on the use of BZD as an alternative to antipsychotics for treating BPSD. However, BZD are widely prescribed to control disruptive behavior and sleep disturbances in AD patients (Hoiseth et al., 2013). Earlier studies in healthy elderly and AD patients have suggested some effectiveness, particularly of those with short half-lives (eg, oxazepam), in treating agitation and aggressive symptoms (Gerz, 1964; Sanders, 1965).

Although good practice guidelines recommend a limited duration of BZD prescription to a few weeks, their use is often chronic and more patients take them for years (American Geriatrics Society Beers Criteria Update Expert, 2012). Long-term treatment with BZD has been associated with an increased risk of falls, dependence, and withdrawal syndromes (Voyer et al., 2010), yet in dementia patients the risk of falls was reported to be slightly more frequent due to antidepressants and antipsychotics (Sterke et al., 2012). Moreover, prior studies in AD patients suggest that BZD worsen cognitive impairment, and lead to a higher rate of side effects such as amnesia, confusion, sedation (Petrovic et al., 2003; Madhusoodanan and Bogunovic, 2004), as well as other adverse drug reactions (ADRs) (Ingum et al., 1994; Allain et al., 2005). The prevalence of such ADRs in patients with AD is estimated to be between 5% and 10% (Onder et al., 2002; Hogan et al., 2003; Laroche et al., 2013).

The current literature suggests that the high rate of BZD-induced side effects in AD is based on disease related changes of pharmacokinetics, pharmacodynamics, and the neurotransmitter system. BZD actions are mediated via gamma-aminobutyric acid A (GABA A) receptors. In contrast to the marked deficits seen in cholinergic and glutamatergic systems in AD brains, the inhibitory GABAergic pathway appears to be more resistant to neurodegeneration and relatively spared (Rissman et al., 2007). This preservation of GABAergic neurons could even support the use of BZD in AD patients. In contrast, radioligand studies have demonstrated a reduction of GABA A-receptor binding sites as well as their function in the frontal and temporal cortices of AD brains (Shimohama et al., 1988; Sasaki et al., 1986; Mizukami et al., 1997). Although prior studies suggest GABAergic remodeling in the brain and an age-dependent reduction of GABA currents (Lim et al., 2012), little is known about the functionality of the GABA A receptor in AD. Evidence from clinical observations suggests that BZD might enhance cognitive decline (Larson et al., 1987; Lopez et al., 1999) and possibly exacerbate steps specific for neurodegeneration in AD, for example, by increasing intraneuronal Aji42 accumulation as shown in a transgenic mice model (Tampellini et al., 2010). However, the findings of experimental studies do not allow for definitive conclusions at this time.

In summary, numerous studies have studied the effect of BZD in the healthy elderly and dementia patients, but results are inconsistent and allow no valid recommendation for the appropriate usage of BZD in patients with AD. Furthermore, studies are often limited by an insufficient description of the study population and fail to provide a critical look deeper into specific substances, dosages, and indications.

We have therefore reviewed the existing literature regarding the use of BZD in patients with AD. We concentrated on high-quality studies, which focus on the effect of BZD on cognitive functions, disease progression, behavioral symptoms, sleep disturbances, and the general frequency of BZD use. All included studies examined BZD use in patients who underwent an established diagnostic setup for AD and provided evidence-based assessments of risks and benefits of BZD in these patients.

Methods

For the purpose of this systematic review, we followed the revised PRISMA guidelines, which have been updated to address several conceptual and practical advances in the science of systematic reviews (Moher et al., 2009). Two independent authors (I.B. and M.D.) undertook the literature search, assessed eligibility, and summarized results. Any discrepancies during these processes were resolved through consensus oriented discussions.

Search

Online published articles from January 1983 to January 2015 were searched using the PubMed/MEDLINE database. To build up the literature search in PubMed, we used the following MeSH terms (Medical Subject Headings, controlled vocabulary thesaurus used for indexing articles): “Alzheimer Disease”[Mesh] AND “Benzodiazepines,”[Mesh] “Alzheimer Disease”[Mesh] AND “Anti-anxiety agents,”[Mesh] and “Alzheimer Disease”[Mesh] AND “Tranquilizing Agents.” Limits were set for: “language English,” “humans,” “full text available,” and “clinical trial.” Furthermore, unpublished studies were searched in the clinical trial registries (http://clinicaltrials.gov/). Additionally, reference lists of relevant articles and related citations found by electronic search were hand-searched for the identification of additional articles using the same search terms as mentioned above.

Selection Criteria

Studies were selected based on the following inclusion criteria: (1) original research papers with prospective or retrospective design (double-blind, placebo-controlled or randomized controlled trials [RCTs], observational studies, population-based studies, cohort studies), (2) AD patients had to be diagnosed according to one of the following diagnostic criteria: the Diagnostic and Statistical Manual of Mental Disorders (DSM) in its third or fourth edition, the International Classification of Diseases in its tenth edition, the National Institute of Neurological and Communicative Disorders and Stroke-AD and Related Disorders Association (NINCDS-ADRDA) criteria (McKhann et al., 1984) or its revised version (Dubois et al., 2007), English language, (4) carried out in humans, (5) published in a peer-reviewed journal, and (6) full text available.

Studies were excluded in case of: (1) missing information regarding applied diagnostic procedure of dementia, (2) dementia was diagnosed based on measures of primary sociobiological functions (Katz-criteria) (Katz and Akpom, 1976), or (3) detection of symptoms of psychological distress, not fulfilling the above mentioned diagnostic criteria of dementia (eg, Helmes et al., 1987).

Outcome Parameters

The 2 primary outcome parameters of this systematic review were: (1) the frequency of BZD use, and (2) the effects of BZD
on cognition functions as well as behavioral and psychological symptoms of dementia, including sleep disturbances in patients with AD or mixed dementia. As secondary outcomes, we extracted information on the following: type of BZD (dose, formulation method), dementia severity, sample size, study duration, and type of study population.

**Results**

A total of 657 articles were identified through the PubMed/MEDLINE database search and assessed for eligibility. Figure 1 shows the stepwise selection procedure and reasons for exclusions. Of 657 identified reports, 18 articles met the predefined inclusion criteria and were included in the review. The articles were divided into 3 categories: (1) frequency of BZD-use in persons with AD, (2) effect of BZD on cognitive functions, and (3) BZD for BPSD and sleep disturbances in AD.

**Frequency of BZD Use in Persons with AD**

We identified 8 eligible studies assessing the frequency of BZD use in patients with AD or mixed dementia. As presented in Table 1, sample size varied from 66 (Steve et al., 2008) to 4,214 patients (Lagnaoui et al., 2003; Koyama et al., 2013; Montastruc et al., 2013). Table 2 provides information on study designs and main findings associated with BZD use. Five studies were designed as prospective and 3 as cross-sectional. As can be seen from Table 5, of these 8 studies, 3 included exclusively AD patients with mild to moderate stages of the disease (MMSE 21–26), reporting a frequency of BZD use ranging from 8.5% (Montastruc et al., 2013) to 20% (Balfour and O’Rourke, 2003; Lagnaoui et al., 2003). In the largest cohort (n = 4,214), examined by Lagnaoui et al. (2003), a MMSE score <24 was associated with less frequent BZD use. A high level of BZD use correlated with high levels of overall drug consumption. Similarly, Steve et al. (2008) reported a positive correlation of low MMSE scores and BZD intake in patients from memory clinics (Steve et al., 2008).

Five studies assessed BZD as Potentially Inappropriate Medication (PIM) in a mixed population of institutionalized patients in nursing homes or care facilities with mild cognitive impairment, severe AD, or mixed dementia (Nobili et al., 2009; Wetzels et al., 2011; Sterke et al., 2012; Koyama et al., 2013; Montastruc et al., 2013). Koyama et al. (2013) analyzed data from a 10-year follow-up study conducted in community-dwelling women with mild to severe cognitive impairment (Table 2). In this study, BZD were the second most prescribed PIMs with a frequency of 8.6%. Overall, percentage of usage of PIMs including BZD showed an increase from 23.9% to 33.1% for women with dementia but remained fairly constant women with no (22.2–19.8% PIMs) or mild cognitive impairment (23.9–23.0% PIMs).

A cohort study by Sterke et al. (2012) found that BZD were the second or third most prescribed psychotropic drugs in nursing home residents. Oxazepam and temazepam were used with highest frequency. In this population, the intake of BZD as well as the combination of BZD with any other psychotropic medication was associated with a significant increase of fall risk in a dose-dependent relationship (Sterke et al., 2012). Wetzels et al. (2011) reported that 9.4% of nursing home residents were treated with BZD continuously for 2 years in another prospective cohort study. BZD along with antidementive medication were more frequently prescribed for residents with AD, whereas residents with vascular dementia more often received antipsychotics, antidepressants, and anticonvulsants.

Nobili et al. (2009) investigated the use of psychotropic drugs among patients with BPSD treated in an Alzheimer special care unit. Approximately 24% of all patients received BZD. Of these 40% were additionally treated with antipsychotics (Table 3). The most frequent coadministered BZD were lorazepam (35%), triazolam (16%), oxazepam (10%), and diazepam (10%). In a French cohort of 684 outpatients with mild to moderate AD (MMSE 10–26), only 8.5% received long-acting BZD (Montastruc et al., 2013).

Balfour and O’Rourke (2003) addressed the important aspect of administering BZD for the treatment of pain, misinterpreted as dementia-related behavior. They showed that BZD were more commonly prescribed for AD patients with arthritis or rheumatism compared with those without these diseases (22% vs 16%).

**Effect of BZD on Cognitive Functions**

We identified 5 studies assessing the effect of BZD on cognition functions in AD patients (Sunderland et al., 1989; Lopez et al., 1999; Ellul et al., 2007; Rosenberg et al., 2012). As shown in Table 5, 4 of 5 studies included exclusively patients suffering from AD.
Rosenberg et al. (2012) examined the association of psychotropic medication use with cognitive, functional, and neuropsychiatric symptom in 224 patients with probable AD during a 12-month period. The effect of multiple drugs including BZD was examined by the Global Deterioration Scale. Longer duration of exposure to psychotropic medication, including BZD, was associated with a more rapid decline in cognition (MMSE) and increase in dementia severity (CDR, NPI). Furthermore, BZD users compared with nonusers showed a 2.8 times higher deterioration rate on the Global Deterioration Scale score.

Lopez et al. (1999) assessed the effect of antidepressants, antipsychotic agents, and BZD (hypnotics, anxiolytics) on cognition, global functioning, and psychiatric symptoms in 179 patients with probable AD during a mean follow-up time of 4.2 years. Although only 6% of the participants took BZD, their use was significantly associated with shorter time to death (RR = 1.96). The frequency of adverse drug reactions (ADRs) in outpatients with suspected dementia was studied in a prospective 1-year follow-up study (Larson et al., 1987). Patients receiving BZD were 5.9 times more likely to have ADRs such as falls.

Table 1. General Study Characteristics

| Population | AD Cases Only | Diagnostic Criteria | Dementia Stage | Age (mean y) | Study Duration (y) | Sample Size |
|------------|---------------|---------------------|----------------|--------------|-------------------|-------------|
| **Frequency of BZD Use** | | | | | | |
| Koyama et al., 2013 | Community-dwelling older women | n.d. | NINCDS-ADRDA | MMSE 26.5 | 87.6 | 10 | 1.484 |
| Montastruc et al., 2013 | Participants living at home | Yes | NINCDS-ADRDA DSM-IV | CDR 1.1 ± 0.6 | 77.9 | 4 | 684 |
| Sterke et al., 2012 | Nursing home residents | n.d. | DSM-IV-TR | GDS 5–6 | 82 | 2 | 284 |
| Wetzels et al., 2011 | Nursing home residents | No | NINCDS-ADRDA | GDS 6–7 | 81.7 | 2 | 117 |
| Nobili et al., 2009 | Residents of special care units | No | Clinical diagnosis | MMSE 7.8 ± 7.0 | 81.2 | 1.5 | 349 |
| Steve et al., 2008 | Memory clinic | No | Clinical diagnosis | MMSE 21.6 ± 7.0 | 74.1 | n.a. | 66 |
| Balfour et al., 2003 | Community dwelling and institutionalized patient | Yes | NINCDS-ADRDA | 3MS 0–77 | 84.3 | n.a. | 460 |
| Lagnaoui et al., 2003 | Community-dwelling and institutionalized patients | Yes | NINCDS-ADRDA DSM-III-R | MMSE > 24 in > 90% cases | 73.2 | 0.25 | 4.214 |
| **BZD effect on cognitive functions** | | | | | | |
| Rosenberg et al., 2012 | Community-dwelling and institutionalized patient | Yes | NINCDS-ADRDA | CDR 5.5* | 86.6 | 3.7 mean | 230 |
| Ellul et al., 2007 | Community-dwelling; nursing homes/primary care Dementia research clinic | Yes | NINCDS-ADRDA | GDS 4–5 | 82.3 | 1 | 257 |
| Lopez et al., 1999 | Dementia research clinic | Yes | NINCDS-ADRDA | MMSE 16–19 | 71.3 | 4.2 mean | 179 |
| Sunderland et al., 1989 | Not mentioned | Yes | NINCDS-ADRDA DSM-III | GDS mild, moderate | 60.1 | 1 and 2 h post drug | 20 |
| Larson et al., 1987 | Mixed population | No | NINCDS-ADRDA | MMSE 19.1 ± 7.9 | 77.1 | 1 | 308 |
| **BZD use for behavioral and sleep disturbances** | | | | | | |
| Liao et al., 2012 | Dementia specialty care unit | Yes | Revised NINCDS-ADRDA | CDR 2 | 59–85 | 7 days | 7 |
| Meehan et al., 2002 | Inpatients | n.d. | NINCDS-ADRDA or DSM IV | MMSE 11.8 ± 7.1 | 77.6 | 24 h | 272 |
| McCarten et al., 1995 | Outpatient men from memory clinic | Yes | NINCDS-ADRDA DSM IV | MMSE 11.6 ± 6.4 | 73 | 8 days | 7 |
| Ancill et al., 1991 | Psychogeriatric Inpatient Unit | No | DSM-III-R | CGI | 78.9 | 28 days | 40 |
| Coccaro et al., 1990 | Chronic care ward | No | DSM-III, NINCDS-ADRDA | CDR 3 | 75.3 | 8 weeks | 52 |

Abbreviations: CDR, Clinical Dementia Rating scale; CGI, Clinical Global Impression; GDS, Global Deterioration Scale; MMSE, Mini-Mental State Examination; 3MS Modified Mini-Mental State Examination; NINCDS-ADRDA, National Institute of Neurological and Communicative Disorders and Stroke-AD and Related Disorders Association; n.a., not applicable; n.d., not determined.

*Represents CDR-sum score.

Table 1 gives information on general characteristics of included studies in this review. As can be seen from the table, there was a high variability of sample size and study duration across the reviewed studies.
and cognitive impairment compared with patients without this medication. These findings are based on the observation of 35 ADRs occurring in 308 patients within study duration. Further, 56% of the patients received BZD monotherapy; the remaining patients used BZDs in combination with other drugs that potentially cause cognitive impairment.

The acute effect of lorazepam 1 mg on memory and cognitive functions was studied in a randomized, placebo-controlled trial (Sunderland et al., 1989). Patients with probable mild-to-moderate AD were compared with healthy controls using standardized neuropsychological tests 1 hour after drug administration. While both groups showed an equal level of sedation,
AD patients showed predominantly attention but no further memory impairments.

**BZD for BPSD and Sleep Disturbances in AD**

We reviewed 5 studies assessing the effect of BZD on behavioral and sleep disturbances. As shown in Table 4, except for one (Liao et al., 2012), all studies employed a prospective design. Two included exclusively AD dementia patients (McCarten et al., 1995; Liao et al., 2012) (Table 1). Meehan et al. (2002) compared the effect of intramuscular lorazepam 1 mg to intramuscular olanzapine or placebo in a double-blind, randomized study of 272 patients with AD or vascular dementia (Table 4). A significant improvement on acute behavioral disturbances (ie, agitation) 2 hours after an intramuscular administration of lorazepam and olanzapine was reported on the PANSS Excited Component scale compared with placebo (-8.5 and -8.7 vs -5.3). ADRs such as drowsiness and dry mouth were more common in the lorazepam group.
Another randomized double-blind study (Ancill et al., 1991) compared the daily oral administration of alprazolam with lorazepam in dementia inpatients with agitation. Treatment response, as measured by the Clinical Global Impression, was 29% on lorazepam and 42% on alprazolam without significant group differences.

Coccaro et al. (1990) examined 52 patients with dementia in an 8-week randomized, double-blind comparison trial of haloperidol (0.5–5 mg/d), oxazepam (10–60 mg/d), and diphenhydramine (25–200 mg/d). Outcome measures included changes in behavioral disturbances and activities of daily living. Results showed modest efficacy for all 3 drugs on behavioral disturbances and a small but not significantly better effect of haloperidol and diphenhydramine compared with oxazepam on activities of daily living.

Table 4. Methodological Characteristics of Included Studies Assessing the Effect of BZDs for Behavioral and Sleep Disturbances

| Study Design                        | Methodology                                                                 | Main Findings Associated with BZD Use                                                                 | Adverse effects of BZD |
|-------------------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|------------------------|
| Liao et al., 2012                   | Retrospective analysis of prospectively collected case series              | Increase incidence of nighttime wandering and day-time restlessness (reversed rest-activity patterns)  | n.d.                   |
| Meehan et al., 2002                 | Multicenter, randomized, double-blind, placebo-controlled                | No effect on sleep time and recent memory deficits                                                  | No significant adverse events in the treatment groups. |
| McCarten et al., 1995               | Open study, placebo - drug - placebo                                      | No effect on sleep time and recent memory deficits                                                  | No side effects concerning sleep and memory related to BZD, risk of falls n.d. |
| Ancill et al., 1991                 | Randomized, double-blind comparison                                       | Nonstatistical significant improvement in agitation of 29% in the lorazepam and 42% in the alprazolam group | Major side effects (ataxia, delirium, oversedation, hypotension): lorazepam n=4, alprazolam n=0; minor side effects (agitation, restlessness): lorazepam n=5, alprazolam n=6 |
| Coccaro et al., 1990                | 8-week randomized, double-blind comparison trial                        | Haloperidol and diphenhydramine showed a not significant greater clinical efficacy compared to oxazepam on improvements in ADL and clinical ratings of behavioral agitation. | Low number of side effects – not further defined, Withdrawal from study caused by oxazepam; extrapyramidal symptoms, oversedation, agitation (n = 1, for each) |

Abbreviations: AD, Alzheimer’s disease; ADL, activities of daily living; BZD, benzodiazepine; i.m., intra muscular; n.d., not determined.

Table 4 summarizes study designs, methodology, and main findings of the 5 studies, which assessed the effect of BZDs for behavioral and sleep disturbances in patients with AD.
Table 5. Percentage of BZD Use of Patients with AD in Selected Study Populations

| Study                                      | N (%) | Patients Treated if AD<100% | AD Patients Treated with BZD |
|--------------------------------------------|-------|-----------------------------|-----------------------------|
| Liao et al., 2012                          | 6 (86) | -                           | 6 (86)                      |
| Meehan et al., 2002                       | n.d.  | 68 (25)                     | n.d.                        |
| McCarten et al., 1995                     | 7 (100)| -                           | 7 (100)                     |
| Ancill et al., 1991                       | n.d.  | 40 (100)                    | n.d.                        |
| Coccaro et al., 1990                      | 52     | 19                          | n.d.                        |

Abbreviations: n.d., not determined; -, not applicable.

*BZD use represents the co-medication to prescribed antipsychotics.

*Indicates number of AD patients of all 35 cases with Adverse Drug Reaction (ADR) causing cognitive impairment.

†Percentage of AD patients determined in another study from the same cohort.

Table 5 shows that detailed information regarding number of especially AD-patients treated with BZDs is missing in approximately 50% of studies assessing the effect of BZD in the elderly.

The interpretation of this study is difficult because of the low number of included AD patients (n=6) and the short assessment period. In a second placebo-controlled study, McCarten et al. (1995) evaluated the effect of a nighttime dose of 125 mg triazolam on 3 consecutive days on sleep and memory function. They found no effects of triazolam on either parameter.

**Discussion**

Despite the common clinical use of BZD in AD patients, there is a worrisome paucity of evidence from well-designed clinical studies. BZD are frequently used in patients with AD, even though their benefit and safety are not convincingly demonstrated. We observed a high degree of heterogeneity of published studies in this systematic review. Since the majority of studies are open-label, conclusions must be considered preliminary.

**Frequency of BZD Use in Persons with AD**

Based on our review, the frequency of BZD use in patients with AD varies between 8.5% and 20%, whereby a much higher prevalence cannot be ruled out as chronic use of BZD has been reported in 50% among nursing home residents, independently of reporting comorbid dementia (Bourgeois et al., 2012). We suggest that the frequency of BZD use depends on the studied population, with a higher percentage in nursing homes and special care units. The majority of studies were heterogeneous regarding patient populations and disease stages of AD. Importantly, the effect of BZD use was often evaluated in conjunction with other psychotropic co-medication such as antipsychotics, anticholinergics, or antidepressants (Nobili et al., 2009; Wetzels et al., 2011; Sterke et al., 2012; Koyama et al., 2013; Montastruc et al., 2013). In most of these studies, the indications for BZD prescriptions were not well defined. For instance, 40% of the residents in Italian Alzheimer special care units receiving antipsychotics were also treated with BZD (Nobili et al., 2009), but neither indication nor dosage were determined.

A comparably low frequency of BZD use (8.5% and 8.6%) was found in 2 studies in community-dwelling elderly in the United States and France (Koyama et al., 2013; Montastruc et al., 2013). Both prospective studies considered BZD as PIM, which may contribute to other comorbidities and impair cognitive function. PIM prescriptions were positively associated with a higher overall drug consumption and female gender. Furthermore, Balfour and O’Rourke (2003) have reported higher rates of BZD prescription in agitated AD patients with musculoskeletal pain compared with patients without pain.

In a large cohort, Lagnaoui et al. (2003) detected a prevalence of BZD use of 20% of cross-sectionally studies institutionalized patients. The frequency of BZD use in nursing homes residents varied considerably depending on the attribution of BZD to subgroups termed anxious and hypnotic drugs and precluded further evaluation. Two studies found a decrease of BZD use with increasing severity of dementia (Lagnaoui et al., 2003; Steve et al., 2008). These results may reflect a rising awareness around safety concerns regarding the use of BZD in very advanced stages of AD.

**Effects of BZD on Cognitive Functions**

Five studies reported a negative effect of BZDs on cognitive functions in AD patients, but a high prevalence of psychotropic...
polypharmacy makes it difficult to judge the effects of BZDs on cognition and behavioral symptoms. Rosenberg et al. (2012), for example, reported that all classes of psychotropic medications including antidepressants, BZD, and antipsychotics were associated with a more rapid decline of cognition in AD patients, suggesting a potentially additive effect of individual psychotropic medications. In support of this, the exclusive use of either antipsychotics or BZD was not significantly associated with the worsening of cognitive, functional, and neuropsychiatric symptoms.

Along the same lines, Ellul et al. (2007) reported that the use of antipsychotics and BZD, but not antidepressants, doubled the risk of at least one-point increase in Global Deterioration Scale over 1 year in 224 patients with AD. Unfortunately, this report lacks details regarding the doses of BZD, specific agents, duration of use, and co-medication patterns. In another longitudinal study, the use of BZD was associated with a twofold increase in mortality risk in patients with AD (Lopez et al., 1999). Antidepressants did not negatively influence outcome. Again, there is no information in this report regarding dose and duration of BZD intake, and only 6% of patients were prescribed BZD.

A high risk of falls has also been affiliated with BZD use in dementia patients as reported by Larson et al. (1987), who found a 5.9 times higher risk of falls as well as accelerated cognitive impairment in BZD users compared with nonusers. However, Sterke et al. (2012) noted a significant dose-related risk of falls in demented nursing home residents not only associated with BZD use but even slightly more frequently with antipsychotics and antidepressants.

Sunderland et al. (1989) examined the effect of a low dose of lorazepam in 10 patients with probable mild-to-moderate AD on memory and other cognitive functions. Lorazepam worsened attention but not memory. Based on these findings, the authors concluded that mild sedation with BZD is not the cause of impairment of higher cognitive functions in AD. These results need to be cautiously interpreted because of the small sample size and missing data on the long-term effects of lorazepam. Based on the available evidence, further investigations should focus on possibly also dose-dependent effect of different BZD, their specific drug metabolism, use in different stages of AD, and duration of BZD treatment.

To sum up, there is a current need to differentiate effects of specific BZD on specific outcome measures including BPSD as for instance agitation, cognitive functions, and sleep disturbances in AD patients. While some substances may be beneficial for certain aspects of BPSD, this cannot be generalized to all behavioral disturbances in the course of AD.

Besides cognitive deficits, noncognitive symptoms such as restlessness, agitation, aggression, depression, and hallucinations are common in AD dementia. These are observed in 60% to 98% in patients with dementia (Mega et al., 1996; Lyketsos et al., 2000). Despite recommendations against the long-term use of BZD in older adults to treat insomnia and agitation (Finkle et al., 2011), the use of these medications remains prevalent (Montastruc et al., 2013).

Three short-time studies have assessed the effect of BZD on BPSD symptoms using a double-blind study design (Coccaro et al., 1990; Ancill et al., 1991; Meehan et al., 2002). Results are inconsistent and suggest a positive effect of BZD in <50% of agitated patients with AD in the short term. A possible explanation for this limited efficacy may be that agitation not only represents a behavioral symptom but also a consequence of misinterpreted or unrecognized needs in persons with dementia (Livingston et al., 2014). Consequently, treatment strategies should consider individual patients’ needs and include both, pharmacological and nonpharmacological interventions. Further, our results show a high number of side effects such as ataxia and delirium (Koyama et al., 2013) associated with BZD use. Therefore, a careful verification of the indication of BZD in patients with AD must be recommended.

Among some additional studies that did not meet our predefined inclusion is a report by Calkin et al. (1997) examining the effect of clonazepam on symptoms such as agitation, anxiety, and psychotic symptoms in demented and nondemented elderly during a treatment period of up to 21 months. Treatment with clonazepam was found to have limited positive but no negative effects on behavioral symptoms in both demented and nondemented patients. Again, the interpretation of this study is limited by small sample size and a high variability in treatment duration and dosage of clonazepam. Even though these studies could not be included in this review, they provide interesting and important considerations for further trials.

There is a lack of evidence for guiding drug treatment of sleep disturbances in AD; insomnia may be the leading indication for chronic BZD use in older adults. Bourgeois et al. (2012) studied 1730 nursing home residents and found a negative association between BZD use and dementia severity. BZD were used in a higher dosages than recommended for older adults. In addition, long-term use of BZD is reported frequently in the elderly, while most clinical trials assess primarily short-term effects. For example, 2 studies over a treatment period of 3 to 7 nights included only 14 patients, 9 of whom had a co-medication with antipsychotics or sedating antidepressants (Table 4). While Liao et al. (2012) reported an increase of reversed rest activity following the administration of brotizolam, McCarten et al. (1995) found no effect of triazolam on sleep or memory functions. There is considerable uncertainty about the risk-benefit balance in this indication supported by a recent Cochrane database review (McCleery et al., 2014).

In summary, since 1983 there are very limited valid data on the effect of BZD in the treatment of behavioral disturbances, agitation, or sleep disorders in AD. Two studies indicate some evidence for a positive effect of lorazepam in the treatment of agitation, but there is no conclusive evidence on the improvement of sleep in response to BZD.

Limitations
Several limitations apply to this review. First, the frequent coadministration of other psychotropic drugs in many of the reviewed studies is a likely source of imprecision. Second, studies included in this review used different criteria for diagnosing dementia. Although, all reported criteria are widely accepted and established, distinct differences between NINCDS-ADRDA, DSM-IV, International Classification of Diseases 10th edition, or DSM-III criteria may limit the comparability of studies. The database restriction and our search strategy may have missed some studies that were not published in PubMed/Medline and studies obtained negative results may not have been published at all. Lastly, there may be relevant information published in languages not included in our search.

Conclusions and Perspectives
In summary, it can be assumed that every fifth to tenth person with AD receives a BZD at least once in the course of the illness. This might reflect a clinical need to treat behavioral symptoms occurring in AD patients; however, there is little evidence on which to base guidelines and recommendations for
safe and effective use of BZDs in these patients. Even though studies addressing specifically dose-related effects of BZD in healthy and demented elderly are rare, early studies with a single administration of triazolam (Greenblatt et al., 1991), for example, support the assumption of age-related differences in pharmacodynamics and pharmacokinetics of BZD in the elderly.

With the exception of acute agitation, we found no evidence for the effective use of BZD in patients with AD but a number of studies reporting negative effects. RCTs examining these effects are the exception. Furthermore, we encountered a number of methodological limiting factors in the available literature.

Therefore, future studies on the benefit-risk profile of BZD in the treatment of behavioral disturbances need to follow the same high-quality scientific standards of clinical trials as for other psychotropic medications. Until such trials become available, clinicians should be well advised to consider alternative management options. These include, for example, citalopram, which has been demonstrated to reduce agitation and caregiver distress in agitated AD patients (Porsteinsson et al., 2014). Similarly, galantamine can be used as a first-line treatment of BPSD symptoms except for prominent irritation and agitation, where risperidone is more efficient (Freund-Levi et al., 2014).

In conclusion, the currently available evidence precludes clear recommendations for an evidenced based use of BZD in patients with AD.

**Statement of Interest**

Dr. Wolfgang W. Fleischhacker is supported by research grants (Otsuka, Janssen Cilag, and Lundbeck), advisory board honoraria (Lundbeck, Roche, Otsuka, Janssen Cilag, Takeda, Amgen, Teva, and Targacept), speaker honoraria (Lundbeck), Janssen Cilag, Otsuka, Roche, and Takeda), and stocks (MedAvante). There are no other conflicts of interest.

**References**

Allain H, Bentue-Ferrer D, Polard E, Akwa Y, Patat A (2005) Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging 22:749–765.

Alzheimer’s Association (2013) 2013 Alzheimer’s disease facts and figures. Alzheimers Dement 9:208–245.

American Geriatrics Society Beers Criteria Update Expert Panel (2012) American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 60:616–631.

Ancill RJ, Carlyle WW, Liang RA, Holliday SG (1991) Agitation in the demented elderly: a role for benzodiazepines? Int Clin Psychopharmacol 6:141–146.

Balfour JE, O’Rourke N (2003) Older adults with Alzheimer disease, comorbid arthritis and prescription of psychotropic medications. Pain Res Manag 8:198–204.

Billioti de Gage S, Begaud B, Bazin F, Verdoux H, Dartigues JF, Peres K, Kurfth T, Pariente A (2012) Benzodiazepine use and risk of dementia: prospective population based study. BMJ 345:e6231.

Billioti de Gage S, Moride Y, Ducruet T, Kurfth T, Verdoux H, Tournier M, Pariente A, Bégaud B (2014) Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ 9:349:g5205.

Bourgeois J, Elseviers MM, Azermai M, Van Bortel L, Petrovic M, Vander Stichele RR (2012) Benzodiazepine use in Belgian nursing homes: a closer look into indications and dosages. Eur J Clin Pharmacol 68:833–844.

Calkin PA, Kunik ME, Orenge CA, Molinari V, Workman R (1997) Tolerability of clonazepam in demented and non-demented geropsychiatric patients. Int J Geriatr Psychiatry 12:745–749.

Coccaro EF, Kramer E, Zemishlany Z, Thorne A, Rice CM 3rd, Giordani B, Duvvi K, Patel BM, Torres J, Nora R, et al. (1990) Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 147:1640–1645.

Dubois B, Feldman HH, Jacora C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O’Brien J, Pasquier F, Robert F, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734–746.

Ellul J, Archer N, Foy CM, Poppe M, Boothby H, Nicholas H, Brown RG, Lovestone S (2007) The effects of commonly prescribed drugs in patients with Alzheimer’s disease on the rate of deterioration. J Neurol Neurosurg Psychiatry 78:233–239.

Finkle WD, Der JS, Greenland S, Adams J, Ridgeway G, Blaschke T, Wang Z, Dell RM, VanRiper KB (2011) Risk of fractures requiring hospitalization after an initial prescription for zolpidem, alprazolam, lorazepam, or diazepam in older adults. J Am Geriatr Soc 59:1883–1890.

Freund-Levi Y, Jedenius E, Tysen-Backstrom AC, Larksater M, Wahlund LO, Eriksdotter M (2014) Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial. Am J Geriatr Psychiatry 22:341–348.

Gertz HO (1964) A Preliminary Report on the Management of Geriatric Patients with Oxazepam. Am J Psychiatry 120:1110–1111.

Greenblatt DJ, Harmatz JS, Shapiro I, Engelhardt N, Gouther TA, Shader RJ (1991) Sensitivity to triazolam in the elderly. N Engl J Med 324:1691–1698.

Helmes E, Csapo KG, Short JA (1987) Standardization and validation of the Multidimensional Observation Scale for Elderly Subjects (MOSES). J Gerontol 42:395–405.

Hogan DB, Maxwell CJ, Fung TS, Ebly EM, Canadian Study of H Aging (2003) Prevalence and potential consequences of benzodiazepine use in senior citizens: results from the Canadian Study of Health and Aging. Can J Clin Pharmacol 10:72–77.

Hoiseth G, Kristiansen KM, Kvande K, Tanum L, Lorentzen B, Refsum H (2013) American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 61:258–263.

Katz S, Akpom CA (1976) A measure of primary sociobiological functions. Int J Health Serv 6:493–508.

Koyama A, Steinman M, Ensrud K, Hillier TA, Yaffe K (2013) Ten-year trajectory of potentially inappropriate medications in very old women: importance of cognitive status. J Am Geriatr Soc 61:258–263.

Lagnauhi R, Begaud B, Moore N, Chislerie A, Fourrier A, Letenneur L, Dartigues JF, Moride Y (2002) Benzodiazepine use and risk of dementia: a nested case-control study. J Clin Epide miol 55:314–318.

Lagnauhi R, Moore N, Moride Y, Miremont-Salame G, Begaud B (2003) Benzodiazepine utilization patterns in Alzheimer’s disease patients. Drug Saf 12:511–515.
Laroche ML, Perault-Pochat MC, Ingrand I, Merle L, Kreft-Jais C, Castot-Villepleat A, Durieu G, Gras V, Guy C, Jean-Pastor MJ, Jonville-Bera AP, Merlet-Chicoine I, Miremont-Salame G, Nourhashemi F, Charpes JF, French Centres of Pharmacovigilance N (2013) Adverse drug reactions in patients with Alzheimer’s disease and related dementia in France: a national multicentre cross-sectional study. Pharmacoepidemiol Drug Saf 22:952–960.

Larson EB, Kukull WA, Buchner D, Reiller BV (1987) Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med 107:169–173.

Liao XY, Yamakawa M, Suto S, Shigenobu K, Makimoto K (2012) Changes in activity patterns after the oral administration of brotizolam in institutionalized elderly patients with dementia. Psychogeriatrics 12:99–105.

Limon A, Reyes-Ruiz JM, Miledi R (2012) Loss of functional GABA(A) receptors in the Alzheimer diseased brain. Proc Natl Acad Sci U S A 109:10071–10076.

Livingston G, Kelly L, Lewis-Holmes E, Bai G, Morris S, Patel N, Omar RZ, Katona C, Cooper C (2014) Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. Br J Psychiatry 205:436–442.

Lopez OL, Wisniewski SR, Becker JT, Rolf F, DeKosky ST (1999) Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer’s disease. Arch Neurol 56:1266–1272.

Lyketsos CG, Steinberg M, Tschand JT, Norton MC, Steffens DC, Breitner JC (2000) Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 157:708–714.

Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S (2002) Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 288:1475–1483.

Madhusoodanan S, Bogunovic OJ (2004) Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf 3:485–493.

Margallo-Lana M, Swann A, O’Brien J, Fairbairn A, Reichelt K, Potkins D, Mynt P, Ballard C (2001) Prevalence and pharmaco-logical management of behavioral and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 16:39–44.

McCarten JR, Kovera C, Maddox MK, Cleary JP (1995) Triazolam in Alzheimer’s disease: pilot study on sleep and memory effects. Pharmacol Biochem Behav 52:447–452.

McCleery J, Cohen DA, Sharpley AL (2014) Pharmacotherapies for sleep disturbances in Alzheimer’s disease. Cochrane Database Syst Rev 3:CD009178.

McKann G, Drachman D, Folstein M, Katzman R, Price D, Stadler J, McCreery J, Cohen DA, Sharpley AL (2014) Pharmacotherapies for Alzheimer’s disease. Neurology 34:939–944.

Meehan KM, Wang H, David SR, Nisisocvicc Jr, Jones B, Beasley CM, Jr, Feldman PD, Mintzer JE, Beckett LM, Breier A (2002) Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 26:494–504.

Mega MS, Cummings JL, Fiorello T, Gornbein J (1996) The spectrum of behavioral changes in Alzheimer’s disease. Neurology 46:130–135.

Mizukami K, Ikonomovic MD, Grayson DR, Rubin RT, Wardle D, Sheffield R, Hamilton RI, Davies P, Armstrong DM (1997) Immuno-histochemical study of GABA(A) receptor beta2/3 subunits in the hippocampal formation of aged brains with Alzheimer-related neuropathologic changes. Exp Neurol 147:333–345.

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006–1012.

Montastruc F, Gardette V, Cantet C, Piau A, Lapeyre-Mestre M, Vellas B, Montastruc JL, Andreu S, Group RF (2013) Potentially inappropriate medication use among patients with Alzheimer disease in the REAL.FR cohort: be aware of atropinic and benzodiazepine drugs! Eur J Clin Pharmacol 69:1589–1597.

Nobili A, Pasina L, Trevisan S, Riva E, Lucca U, Tettamanti M, Matusci M, Tarantola M (2009) Use and misuse of antipsychotic drugs in patients with dementia in Alzheimer special care units. Int Clin Psychopharmacol 24:97–104.

Onder G, Gambassi G, Scales CJ, Cesarini M, Vedova CD, Landi F, Bernabei R (2002) Adverse drug reactions and cognitive function among hospitalized older adults. Eur J Clin Pharmacol 58:371–377.

Petrovic M, Mariman A, Warie H, Afshar M, Pevernagie D (2003) Is there a rationale for prescription of benzodiazepines in the elderly? Review of the literature. Acta Clin Belg 58:27–36.

Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meintner CL, Mintzer JE, Munro CA, Felton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub DS, Yesavage J, Lyketsos CG, Cit ADRC (2014) Effect of cilostopram on agitation in Alzheimer disease: the CilAD randomized clinical trial. JAMA 311:682–691.

Rissman RA, De Blas AL, Armstrong DM (2007) GABA(A) receptors in aging and Alzheimer’s disease. J Neurochem 103:1285–1292.

Rosenberg PB, Mielke MM, Han D, Leoutsakos JS, Lyketsos CG, Rabins PV, Zandi PP, Breitner JC, Norton MC, Welsh-Bohmer KA, Zuckerman IH, Rattinger GB, Green BC, Corcoran C, Tschand JT (2012) The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer’s disease. Int J Geriatr Psychiatry 27:1248–1257.

Sanders JF (1965) Evaluation of Oxazepam and Placebo in Emotionally Disturbed Aged Patients. Geriatrics 20:739–746.

Sasaki H, Muramoto O, Kanazawa I, Arai H, Kosaka K, Iizuka R (1986) Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type. Ann Neurol 19:263–269.

Shimohama S, Taniguchi T, Fujinawa M, Kameyama M (1988) Changes in benzodiazepine receptors in Alzheimer-type dementia. Ann Neurol 23:404–406.

Sterke CS, van Beeck EF, van der Velde N, Ziere G, Petrovic M, Looman CW, van der Cammen TJ (2012) New insights: dose-response relationship between psychotropic drugs and falls: a study in nursing home residents with dementia. J Clin Pharmacol 52:947–955.

Steve TA, Kirk A, Crossley M, Morgan D, D’Arcy C, Biem J, Forbes T, Donovan V, Segelmann F, Charmes JP, French Centres of Pharmacovigilance N (2013) Prescribing pattern of psychotropic drugs in nursing home residents with dementia. Int J Clin Pharmacol 58:52–57.

Tampellini D, Capetillo-Zarate E, Dumont M, Huang Z, Yu F, Lin MT, Gouras GK (2010) Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer’s disease transgenic mice. Front Aging Neurosci 30:14299–14304.

Voyer P, Roussel ME, Berbiche D, Preville M (2010) Effectively detect dependence on benzodiazepines among community-dwelling seniors by asking only two questions. Ment Health Nurs 17:328–334.

Wetzels RB, Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT (2011) Prescribing pattern of psychotropic drugs in nursing home residents with dementia. Int Psychogeriatr 23:1249–1259.